A WHO collaborative study on viral hepatitis B in which 21 laboratories in 20 countries participated is described. The aim of the study was to define the prevalence of hepatitis B surface antigen (HBsAg), its subtypes, and its antibody (anti-HBs) by age and sex and urban or rural residence in normal populations in different parts of the world. High-risk groups in the populations and patients with various diseases were also investigated. The results of the study confirmed that HBsAg and anti-HBs prevalence rates were higher in African and Asian countries than in the Americas, Australia, and northern and central Europe. Some eastern and southern European countries, however, were also shown to have high HBsAg and anti-HBs prevalence rates, comparable with those in Africa and Asia. In countries with low HBsAg and anti-HBs prevalence, there seems to be a gradual build-up during late childhood or early adolescence, whereas in countries with high HBsAg and its antibody prevalence, they were frequently detected in preschool children. Although the trend was towards a higher frequency of HBsAg and anti-HBs in urban than in rural and in male than in female populations, the differences were in most cases not significant. On the other hand, a significantly higher prevalence of markers of hepatitis B virus infection was seen in high-risk population groups than in normal populations. This was, however, clearly defined only in areas with low HBsAg and anti-HBs prevalence in the normal population. The geographical distribution of HBsAg subtypes showed a higher prevalence of the ad subdeterminant over ay in central European countries, whereas in eastern and southern Europe the ay subtype predominated. In West Africa, ayw was the only variant found, whereas in East Africa ad occurred more frequently than ay. In Australia, both adw and ayw subtypes were detected, whereas in the Far East and South-east Asia only adw and adr were seen.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395942 | PMC |
Viruses
December 2024
Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy.
The effects of a concomitant infection of hepatitis B virus (HBV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are still debated, with a recognized major risk of HBV reactivation during immune-suppressive treatments. The aim of this study was to determine the prevalence and predictive factors of HBV reactivation in a cohort of hospitalized patients with coronavirus disease 2019 (COVID-19) and a current or past hepatitis B infection. In a monocentric retrospective observational study, we enrolled all consecutive hospital admitted patients with COVID-19 pneumonia and a positive HBV serology (N = 84) in our Infectious Diseases Unit from April 2021 to December 2023.
View Article and Find Full Text PDFACS Omega
January 2025
Suzhou Hepa Thera Biopharmaceutical Company Limited, Shanghai 200120, China.
Current antiviral therapy for the chronic hepatitis B virus (HBV) has a low clinical cure rate, high administration frequency, and limited efficacy in reducing HBsAg levels, leading to poor patient compliance. Novel agents are required to achieve HBV functional cure, and reduction of HBV antigenemia may enhance the activation of effective and long-lasting host immune control. HT-101 is a siRNA currently in phase I clinical trials with promising prospects for future applications.
View Article and Find Full Text PDFVaccine
January 2025
Zhengding County Center for Disease Control and Prevention, Shijiazhuang 050800, China. Electronic address:
To evaluate the long-term efficacy and anamnestic response of Chinese hamster ovary (CHO) cell-derived hepatitis B vaccine (CHO-HepB) after 18-20 years, a cross-sectional survey was conducted in seven communities in Zhengding County at the end of 2017. The birth cohort 1997-1999 vaccinated primarily with three doses of CHO-HepB were enrolled in the survey. The HBV serological markers were quantified using the Chemiluminescence method.
View Article and Find Full Text PDFClin Exp Med
January 2025
Guangzhou Huayin Health Medical Group Co., Ltd, Guangzhou, 510515, China.
Coexistence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) has been observed in some chronic hepatitis B (CHB) patients (DP patients), but the clinical outcomes and comprehensive characterization of immune micro-environmental changes for this specific population remain inconclusive. In this study, we retrospectively analyze the prognosis of 305 patients in Foshan City, Guangdong Province, China, and also investigated the molecular immunology changes in HBsAg and anti-HBs double positive CHB patients (DP group), CHB patients who had recovered from IFN-ɑ treatment (RP group), and healthy controls (HC group) using T cell receptor (TCR) and B cell receptor (BCR) immune repertoire sequencing. Our findings revealed that 22.
View Article and Find Full Text PDFSci Rep
January 2025
Centers of Excellence in Clinical Virology, Chulalongkorn University, Bangkok, Thailand.
This study aimed to evaluate the impact of Thailand's hepatitis B virus (HBV) National Program Immunization (NPI), 32 years post-implementation, on infection rates and immunity in various age groups. A cross-sectional study involved 6,068 participants aged 6 months to 80 years from four regions in Thailand. Blood samples were tested for HBsAg, anti-HBs, and anti-HBc using a chemiluminescent immunoassay.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!